Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
•To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA < LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. •To evaluate the safety and tolerability of MK-5172A as compared to SOF/PR.
Critère d'inclusion
- Hepatitis C